Influence of 3-aminobenzamide, an inhibitor of poly(ADP-ribose)polymerase, in the evaluation of the genotoxicity of doxorubicin, cyclophosphamide and zidovudine in female mice

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 770, Issue , 2014, Pages 6-15

  Yadav, L ^a   Khan, S ^a   Shekh, K ^a   Jena, G B ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Chromosome aberration; Comet; Genotoxicity; Micronucleus; PARP inhibitor; Weak genotoxins

Indexed keywords

3 AMINOBENZAMIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SUCROSE; ZIDOVUDINE; 3-AMINOBENZAMIDE; BENZAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHROMOSOME ABERRATION; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; FEMALE; GENOTOXICITY; HISTONE PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; LIVER; MICRONUCLEUS; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOASSAY; DRUG EFFECTS; LYMPHOCYTE; METABOLISM; MUTAGEN TESTING; PHOSPHORYLATION; TOXICITY;

ANIMALS; BENZAMIDES; CHROMOSOME ABERRATIONS; COMET ASSAY; CYCLOPHOSPHAMIDE; DNA DAMAGE; DOXORUBICIN; ENDPOINT DETERMINATION; FEMALE; LIVER; LYMPHOCYTES; MICE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; SUCROSE; ZIDOVUDINE;

EID: 84901801633     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2014.04.020     Document Type: Article

References (44)

1. Muller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., Tweats D. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat. Res. 1999, 436:195-225.
2. Müller L., Tweats D., Galloway S., Hayashi M. The evolution, scientific reasoning and use of ICH S2 guidelines for genotoxicity testing of pharmaceuticals. Global Approach in Safety Testing 2013, 77-118. Springer.
3. Burlinson B., Tice R.R., Speit G., Agurell E., Brendler-Schwaab S.Y., Collins A.R., Escobar P., Honma M., Kumaravel T.S., Nakajima M., Sasaki Y.F., Thybaud V., Uno Y., Vasquez M., Hartmann A. Fourth international workgroup on genotoxicity testing: results of the in vivo comet assay workgroup. Mutat. Res. 2007, 627:31-35.
4. Kissling G.E., Dertinger S.D., Hayashi M., MacGregor J.T. Sensitivity of the erythrocyte micronucleus assay: dependence on number of cells scored and inter-animal variability. Mutat. Res. 2007, 634:235-240.
5. Kasper P., Uno Y., Mauthe R., Asano N., Douglas G., Matthews E., Moore M., Mueller L., Nakajima M., Singer T., Speit G. Follow-up testing of rodent carcinogens not positive in the standard genotoxicity testing battery: IWGT workgroup report. Mutat. Res. 2007, 627:106-116.
6. Benigni R., Bossa C., Tcheremenskaia O., Battistelli C.L., Crettaz P. The new ISSMIC database on in vivo micronucleus and its role in assessing genotoxicity testing strategies. Mutagenesis 2012, 27:87-92.
7. LeBaron M.J., Schisler M.R., Torous D.K., Dertinger S.D., Gollapudi B.B. Influence of counting methodology on erythrocyte ratios in the mouse micronucleus test. Environ. Mol. Mutagen. 2013, 54:222-228.
8. Tilmant K., Gerets H.H., De Ron P., Cossu-Leguille C., Vasseur P., Dhalluin S., Atienzar F.A. The automated micronucleus assay for early assessment of genotoxicity in drug discovery. Mutat. Res. 2013, 751:1-11.
9. Torous D.K., Phonethepswath S., Avlasevich S.L., Mereness J., Bryce S.M., Bemis J.C., Weller P., Bell S., Gleason C., Custer L.L., MacGregor J.T., Dertinger S.D. In vivo flow cytometric pig-a and micronucleus assays: highly sensitive discrimination of the carcinogen/noncarcinogen pair benzo(a)pyrene and pyrene using acute and repeated-dose designs. Environ. Mol. Mutagen. 2012, 53:420-428.
10. Azqueta A., Arbillaga L., Lopez de Cerain A., Collins A. Enhancing the sensitivity of the comet assay as a genotoxicity test, by combining it with bacterial repair enzyme FPG. Mutagenesis 2013, 28:271-277.
11. Bhalli J.A., Ding W., Shaddock J.G., Pearce M.G., Dobrovolsky V.N., Heflich R.H. Evaluating the weak in vivo micronucleus response of a genotoxic carcinogen, aristolochic acids. Mutat. Res. 2013, 753:82-92.
12. Kirkland D., Aardema M., Henderson L., Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584:1-256.
13. Qiu Y.L., Wang W., Wang T., Sun P., Wu F., Zhu S.M., Qian J., Jin L., Au W., Xia Z.L. DNA repair gene polymorphisms and micronucleus frequencies in Chinese workers exposed to vinyl chloride monomer. Int. J. Hyg. Environ. Health 2011, 214:225-230.
14. Garcia-Leston J., Roma-Torres J., Vilares M., Pinto R., Prista J., Teixeira J.P., Mayan O., Conde J., Pingarilho M., Gaspar J.F., Pasaro E., Mendez J., Laffon B. Genotoxic effects of occupational exposure to lead and influence of polymorphisms in genes involved in lead toxicokinetics and in DNA repair. Environ. Int. 2012, 43:29-36.
15. Surova O., Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene 2013, 32:3789-3797.
16. Herceg Z., Wang Z.Q. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res. 2001, 477:97-110.
17. Jagtap P., Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4:421-440.
18. Al-Ejeh F., Shi W., Miranda M., Simpson P.T., Vargas A.C., Song S., Wiegmans A.P., Swarbrick A., Welm A.L., Brown M.P., Chenevix-Trench G., Lakhani S.R., Khanna K.K. Treatment of triple-negative breast cancer using anti-EGFR directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J. Nucl. Med. 2013, 54:913-921.
19. Do K., Chen A.P. Molecular pathways: targeting PARP in cancer treatment. Clin. Cancer Res. 2013, 19:977-984.
20. Booth L., Cruickshanks N., Ridder T., Dai Y., Grant S., Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol. Ther. 2013, 14:49-50.
21. Jesser M., Chypre C., Hog F., Mandel P. Cytoplasmic poly(ADP-ribose)polymerase from mouse plasmacytoma free messenger ribonucleoprotein particles: purification and characterization. Biochem. Biophys. Res. Commun. 1993, 195:558-564.
22. Rossi M.N., Carbone M., Mostocotto C., Mancone C., Tripodi M., Maione R., Amati P. Mitochondrial localization of PARP-1 requires interaction with mitofilin and is involved in the maintenance of mitochondrial DNA integrity. J. Biol. Chem. 2009, 284:31616-31624.
23. von Minckwitz G., Muller B.M., Loibl S., Budczies J., Hanusch C., Darb-Esfahani S., Hilfrich J., Weiss E., Huober J., Blohmer J.U., du Bois A., Zahm D.M., Khandan F., Hoffmann G., Gerber B., Eidtmann H., Fend F., Dietel M., Mehta K., Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J. Clin. Oncol. 2011, 29:2150-2157.
24. Germain M., D'Amours D., Dixit V.M., Salvesen G.S., Poirier G.G. Cleavage of automodified poly (ADP-ribose) polymerase during apoptosis evidence for involvement of caspase-7. J. Biol. Chem. 1999, 274:28379-28384.
25. Pandya K.G., Patel M.R., Lau-Cam C.A. Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. J. Biomed. Sci. 2010, 17(1):S16.
26. Zhao Y.J., Wang J.H., Fu B., Ma M.X., Li B.X., Huang Q., Yang B.F. Effects of 3-aminobenzamide on expressions of poly(ADP-ribose) polymerase and apoptosis inducing factor in cardiomyocytes of rats with acute myocardial infarction. Chin. Med. J. (Engl.) 2009, 122:1322-1327.
27. Czapski G.A., Cakala M., Gajkowska B., Strosznajder J.B. Poly(ADP-ribose) polymerase-1 inhibition protects the brain against systemic inflammation. Neurochem. Int. 2006, 49:751-755.
28. Dinant C., Houtsmuller A.B., Vermeulen W. Chromatin structure and DNA damage repair. Epigenetics Chromatin 2008, 1:9.
29. Lim H.K., Asharani P.V., Hande M.P. Enhanced genotoxicity of silver nanoparticles in DNA repair deficient mammalian cells. Front. Genet. 2012, 3:104.
30. Kawaguchi S., Nakamura T., Yamamoto A., Honda G., Sasaki Y.F. Is the comet assay a sensitive procedure for detecting genotoxicity?. J. Nucleic Acids 2010, 2010:541050.
31. Kirkland D., Kasper P., Muller L., Corvi R., Speit G. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. Mutat. Res. 2008, 653:99-108.
32. He J.X., Yang C.H., Miao Z.H. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol. Sin. 2010, 31:1172-1180.
33. Cooper D.L., Lovett S.T. Toxicity and tolerance mechanisms for azidothymidine, a replication gap-promoting agent, in Escherichia coli. DNA Repair (Amst.) 2011, 10:260-270.
34. Hastwell P.W., Chai L.L., Roberts K.J., Webster T.W., Harvey J.S., Rees R.W., Walmsley R.M. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the greenscreen HC gadd45a-gfp genotoxicity assay. Mutat. Res. 2006, 607:160-175.
35. Mughal A., Vikram A., Kushwaha S., Jena G.B. Simultaneous use of erythropoietin and prior bleeding enhances the sensitivity of the peripheral blood micronucleus assay. Mutagenesis 2011, 26:331-338.
36. Trivedi P.P., Tripathi D.N., Jena G.B. Hesperetin protects testicular toxicity of doxorubicin in rat: role of nfkappab, p38 and caspase-3. Food Chem. Toxicol. 2011, 49:838-847.
37. Ahmad T., Shekh K., Khan S., Vikram A., Yadav L., Parekh C.V., Jena G.B. Pretreatment with valproic acid, a histone deacetylase inhibitor, enhances the sensitivity of the peripheral blood micronucleus assay in rodents. Mutat. Res. 2013, 751:19-26.
38. Sun J.T., Armstrong M.J., Galloway S.M. Rapid method for improving slide quality in the bone marrow micronucleus assay; an adapted cellulose column procedure. Mutat. Res. 1999, 439:121-126.
39. Khan S., Jena G. Sodium valproate, a histone deacetylase inhibitor ameliorates cyclophosphamide-induced genotoxicity and cytotoxicity in the colon of mice. J. Basic Clin. Physiol. Pharmacol. 2014, 1-11. 10.1515/jbcpp-2013-0134.
40. Tripathi D.N., Jena G.B. Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice. Free Radic. Res. 2008, 42:966-977.
41. Taylor R. Interpretation of the correlation coefficient: a basic review. J. Diagn. Med. Sonography 1990, 6:35-39.
42. Liu Y., Tseng M., Perdreau S.A., Rossi F., Antonescu C., Besmer P., Fletcher J.A., Duensing S., Duensing A. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res. 2007, 67:2685-2692.
43. Jung E.J., Kim D.R. Ectopic expression of H2AX protein promotes TRKA-induced cell death via modulation of TRKA tyrosine-490 phosphorylation and JNK activity upon DNA damage. Biochem. Biophys. Res. Commun. 2011, 404:841-847.
44. Ström C.E., Helleday T. Strategies for the use of poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy. Biomolecules 2012, 2:635-649.